Gamma polyglutamated pralatrexate and uses thereof
AssigneeL.E.A.F. Holdings Group LLC
InventorsClet NIYIKIZA, Victor Mandla MOYO
Life of this patent
Estimating the term…
Abstract
The disclosure relates generally to gamma polyglutamated pralatrexate compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated pralatrexate, and methods of making and using the gamma polyglutamated pralatrexate compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis).
Claims22
1-94. (canceled)
A liposomal composition comprising a gamma polyglutamated pralatrexate encapsulated by a liposome, wherein the polyglutamated pralatrexate has 4, 5, 2-10, 4-6, or more than 5, glutamyl groups in the D-form having gamma carboxyl group linkages,
- wherein the liposome is pegylated and does not contain a targeting moiety having specific affinity for a surface antigen on a target cell,
- wherein the liposome does not contain a cell penetrating peptide and does not contain a mitochondria penetrating agent,
- wherein the liposome has a zeta potential that is less than or equal to zero, between 0 and −150 mV, or between −30 and −50 mV, and
- wherein the liposome is capable of delivering the gamma polyglutamated pralatrexate directly into a cell.
The method of claim 20, wherein the hyperproliferative cell is a cancer cell, a mammalian cell, and/or a human cell.
Dependencies are inferred from the claim text.